Larsoz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing the movement of the stomach and intestines, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two active ingredients makes Larsoz-DSR particularly beneficial for patients experiencing both acid reflux and impaired gastric motility. It is indicated for the treatment of GERD with associated dyspeptic symptoms and delayed gastric emptying. Larsoz-DSR should be administered as prescribed by a healthcare professional, with caution advised in patients with cardiac arrhythmias, liver impairment, or those taking medications that may interact with domperidone or esomeprazole. Regular monitoring is recommended to assess therapeutic efficacy and detect potential adverse effects. This combination therapy offers a comprehensive approach to managing complex upper gastrointestinal conditions.